Laparoscopic removal of an accessory spleen for recurrent idiopathic thrombocytopenic purpura 5 years after laparoscopic splenectomy using perioperative eltrombopag conditioning
- 109 Downloads
Treatment of idiopathic thrombocytopenic purpura (ITP) refractory to medical management consists of splenectomy with a high success rate. Recurrent ITP may be due to re-growth of a missed accessory spleen.
The clinical course of a 59-year-old female who had undergone laparoscopic splenectomy for ITP refractory to medical management 5 years ago developed a sudden drop in her platelet count to as low as 1 K/ml and she developed purpura.
On liver/spleen scan and CT scan a 5 × 5 cm mass containing splenic tissue was found close to the tail of the pancreas. Eltrombopag (Promacta®) was used to stabilize her platelet count. During laparoscopy dense adhesion of the omentum to the abdominal wall and stomach from her previous splenectomy had to be divided. The colon was identified, the lesser sack opened through the gastrocolic ligament and the splenic flexure was taken down. The stomach was lifted anteriorly and medially to expose the tail of the pancreas and superior and dorsal to the pancreas at the previous splenic hilum the mass was identified and carefully dissected off the pancreas, kidney and adrenal gland. An endo GI with a white load was used to divide the vascular pedicle, which originated from a side branch of the splenic artery and splenic vein at the tail of the pancreas and secured with an endoloop. The accessory spleen was placed into an endobag, cut in small pieces and removed through the 10–12 mm port. The patient recovered well from the procedure without any complications and her platelet count normalized within a few weeks.
Re-growth of splenic tissue causing recurrent ITP is a rare condition but should be considered. Laparoscopic removal of accessory spleens can be safely done. Newly developed agents are helpful in the management of ITP patients.
KeywordsSplenectomy ITP Accessory spleen Eltrombopag Laparoscopy
Conflict of interest
H. Bonatti, D. Medina, N. Kubicki, and S. Kavic declare that they have no competing interests.
- 2.Rodriguez-Otero Luppi C, Targarona Soler EM, Balague Ponz C, Pantoja Millan JP, Turrado Rodriguez V, Pallares Segura JL, et al. Clinical, anatomical, and pathological grading score to predict technical difficulty in laparoscopic splenectomy for non-traumatic diseases. World J Surg. 2016; doi: 10.1007/s00268-016-3683-y.CrossRefGoogle Scholar
- 7.Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, et al. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol. 2012;158(6):798–800.CrossRefGoogle Scholar
- 8.Ruiz-Arguelles GJ, Ruiz-Delgado GJ, Velazquez-Sanchez-de-Cima S, Zamora-Ortiz G. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Hematology. 2013;18(3):175–7.CrossRefGoogle Scholar
- 9.Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331–4.CrossRefGoogle Scholar